Activin induces proliferation in epithelial ovarian carcinoma cell lines, whereas follistatin (FS), an activin binding protein, inhibits this action. To test the hypothesis that activin production, in excess of inhibin and FS, results in cell proliferation in epithelial ovarian tumors, messenger RNA (mRNA) expression of the activin family of proteins, FS, and activin type I and II receptors was examined in 25 primary epithelial ovarian tumors and tumor epithelium in culture (n ϭ 7) using RT-PCR. Activin A was measured in the serum of ovarian cancer patients, and activin A, total inhibin, and FS protein secretion was measured from primary epithelial tumors in vitro. The effect of activin and FS on cell proliferation was assessed by measuring [ 3 H]thymidine incorporation. All results were compared with normal ovarian epithelium.
Activin protein was secreted by 24/25 primary epithelial ovarian tumors (range 0.2-155.8 ng/mL). In contrast, total inhibin was secreted by only 2/25 (range 0.01-0.92 ng/mL), whereas free FS was not detectable in the medium of any tumor (Ͻ0.5 ng/mL). Treatment with activin or FS did not consistently affect cell growth. Measurement of serum activin A in a subset of subjects and in 27 additional subjects with epithelial ovarian carcinoma (n ϭ 33) revealed preoperative activin A levels Ͼ3 SD above the mean for pre-and postmenopausal women in 13/33 (39%) subjects.
We conclude that in epithelial ovarian cancer: 1) ␤A subunit mRNA is expressed, 2) activin protein is secreted more frequently than inhibin and in greater quantities than FS, 3) ␤A subunit mRNA expression is greater in neoplastic and normal epithelium in culture than in the primary tissue, 4) the majority of tumors in culture do not respond to activin or FS treatment with proliferation, and 5) serum activin levels may reflect tumor secretion in some patients. Thus, activin A appears to be available as an autocrine/paracrine factor in epithelial ovarian tumors and may contribute to circulating levels, but its role in tumorigenesis has yet to be defined. (J Clin Endocrinol Metab 82: 3720 -3727, 1997) O VARIAN cancer is the fifth most common malignancy in women in the United States (1), yet little is understood about its etiology and less about its pathogenesis. Eighty-seven percent of ovarian cancers are epithelial in origin (2) . There appears to be a decreased risk of ovarian neoplasia with circumstances that decrease ovulatory frequency such as increased parity, breast feeding, and oral contraceptive use (3) , whereas some studies seem to show an increased risk with the use of infertility drugs, although this finding remains controversial (3) (4) (5) . These epidemiological findings suggest that suppression of folliculogenesis may be an important factor in decreasing the risk of epithelial ovarian cancer.
Inhibin and activin are members of the transforming growth factor-␤ superfamily. Inhibin is composed of an ␣ and one of two ␤ subunits, ␣␤A (inhibin A) or ␣␤B (inhibin B). Activin is a related dimeric protein composed of two ␤ subunits, ␤A ␤A (activin A), ␤B ␤B (activin B), or ␤A ␤B (activin AB) (6) . Elevated levels of inhibin and its subunits have been detected in subjects with a variety of gonadal stromal tumors (7) (8) (9) , most commonly granulosa cell tumors (10 -12) . In addition, elevated inhibin levels have been detected in subjects with epithelial ovarian carcinomas, predominantly mucinous cystadenocarcinomas and mucinous borderline cystic tumors (13) .
There is also evidence that the activin family of proteins plays a key role in ovarian tumor growth. Deletion of the inhibin ␣ subunit in a transgenic mouse model results in development of gonadal stromal tumors (14) and elevated circulating activin levels (15) , suggesting that loss of the ␣ subunit and/or overproduction of activin results in tumorigenesis. A recent study of six human epithelial ovarian cancer cell lines revealed absence of inhibin ␣ subunit expression and secretion, and the presence of the activin type II receptor and ␤A and/or ␤B subunit expression and secretion (16) . In these ovarian cancer cell lines and in a cell line derived from a gonadal tumor of an ␣ subunit knockout mouse, activin treatment resulted in increased proliferation, whereas follistatin (FS), an activin binding and neutralizing protein (17) (18) (19) , decreased proliferation in the cell lines producing activin (16, 20) .
Taken together, these studies suggest that ␤A subunit messenger RNA (mRNA) expression and activin secretion in excess of FS and/or in the absence of ␣ subunit results in increased bioavailable activin, which may ultimately contribute to growth of epithelial ovarian tumors. To test this hypothesis, expression of ␣, ␤A, and ␤B subunits; FS; and activin type I and II receptor mRNA was examined in 25 primary epithelial ovarian tumors and in a pure population of epithelium cultured from tumors (n ϭ 7). Activin A, total inhibin, and FS protein secretion was measured from primary epithelial ovarian tumors in vitro. mRNA expression and protein secretion from primary tumors were compared with results derived from the epithelium of 9 normal ovaries and normal ovarian epithelium in culture (n ϭ 2). Circulating activin A levels were also measured in a subset of these patients and in 27 additional subjects with epithelial ovarian carcinoma (n ϭ 33). The resulting demonstration of ␤A subunit mRNA expression and activin A protein secretion in epithelial ovarian tumors but not normal epithelium, the increase in ␤A subunit expression in neoplastic and normal epithelium propagating in culture, along with the elevated serum activin A levels in a subset of subjects with epithelial ovarian carcinoma suggest that activin may be a factor contributing to tumorigenesis in these patients.
Materials and Methods

Collection and processing of tissue and protein samples
Epithelial ovarian tumors. Epithelial tumor tissue (ϳ1 g) was removed by the pathologist from a nonnecrotic portion of the surgical specimen (n ϭ 25). Epithelial tumor subtypes included 1 borderline serous, 13 serous, 4 endometrioid, 1 borderline mucinous, 3 mucinous, and 3 clear cell carcinomas. Tissue was placed in sterile Dulbecco's PBS and transported, on ice, to the laboratory within 18 h (usually Ͻ4 h) of the surgery. Tissue was flash frozen and stored at Ϫ80 C for later mRNA extraction (see below). In addition, 0.1-0.4 g of tissue was processed using the explant method (21) in 10 mL RPMI-1640, supplemented with 10% FCS, 2 mm l-glutamine and antibiotics (100 IU/mL penicillin and 100 g/mL streptomycin sulfate). The tissue was incubated at 37 C in a 5% carbon dioxide atmosphere for 1 week to allow accumulation of sufficient hormone for detection while still reflecting secretion of the primary tumor. Medium was collected, centrifuged to remove tissue, and stored at Ϫ20 C until assayed.
Normal epithelium. Normal ovarian surface epithelium was obtained from 11 control subjects who underwent oophorectomy for a nonovarian cause. Epithelium was scraped from the ovarian surface using a disposable cell scraper (22) and placed in sterile Dulbecco's PBS on ice. Cells were immediately centrifuged, and the resulting pellet resuspended in 1 mL of Trizol (Gibco BRL, Grand Island, NY) for subsequent mRNA extraction (n ϭ 9) or in RPMI-1640 medium supplemented as above for protein analysis (n ϭ 2).
The procedure for collection of all specimens was approved by the Subcommittee on Human Studies at the Massachusetts General Hospital.
Culture of primary tumors and normal epithelium
Cells remaining after removal of medium for hormone assay were maintained in culture by changing medium weekly, subculturing after cells reached approximately 80% confluence (1 week to 1 month), and removing fibroblasts using selective trypsin treatment (21) . To assure that RNA was extracted from a pure population of epithelial tumor cells, the identity of cells in culture was confirmed by positive immunohistochemical staining using mouse antiserum against human cytokeratin (AE1/AE3) and negative staining using mouse antiserum against human desmin (D33) (Dako Corp., Carpinteria, CA). If subculture of cells for immunohistochemistry was impossible because of inadequate growth, morphology was assessed using previously described methods (23, 24) . In general, Ͻ10% of the cells were nonepithelial by morphology. Because of the failure of many epithelial carcinomas to grow in culture (21) and the slow growth of others, a total of six tumor cultures were used after 3 weeks in proliferation studies and seven cultures were used after 1 month for mRNA extraction and RT-PCR.
Collection of serum samples
After obtaining written informed consent, excess serum or plasma was obtained from preoperative surgical testing and at least 48 h postoperatively in 6 subjects, age 51-75 yr, undergoing surgery for epithelial ovarian cancer. Tumor tissue from the same subject was analyzed as described below. An additional 27 preoperative serum samples and 9 paired postoperative samples were obtained after CA-125 testing from a separate group of subjects with epithelial ovarian cancer, age 40 -80 yr. Control subjects included 8 healthy postmenopausal and castrate women, age 51-64 yr, and 6 premenopausal women, age 26 -38 yr, with normal menstrual cycles as described previously (25) . The blood sample was obtained on the day of menses for premenopausal women to reflect the peak activin A levels in the menstrual cycle (26) . The procedures were approved by the Subcommittee on Human Studies at the Massachusetts General Hospital and at Women and Infants' Hospital of Rhode Island.
Protein measurement
Total inhibin RIA (Monash RIA). Total inhibin was measured using the Monash RIA with antiserum 1989 provided by Dr. G. Bialy, Contraceptive Development Branch, NICHD, as described previously (16) . The inter-and intraassay coefficients of variation were 12% and 10% respectively. The assay sensitivity was 75 pg/mL. This assay recognizes monomeric forms of ␣-inhibin as well as dimeric inhibin (27) via an epitope at the C terminus of the mature ␣ subunit (aa 93-108) (28) .
Dimeric inhibin A two-site enzyme-linked immunosorbent assay (ELISA).
Dimeric inhibin A was measured in samples with elevated total inhibin using a commercially available ELISA (Serotec Ltd., Oxford, England), as previously described (29) . The intraassay coefficient of variation was 9.0%, and the interassay coefficient of variation was 6.8%. The assay sensitivity was 1 pg/mL, and cross-reactivity with inhibin B and activin A was Ͻ0.5%.
Activin A ELISA. Total activin A was measured in a two-site solid-phase assay, using a monoclonal antibody against the ␤A subunit of inhibin (E4; aa 82-114; 250 ng/well) (Serotec) for both capture and detection according to previously published methods, except where specified (30) . Human recombinant activin A, purified in our laboratory from medium conditioned by 293 cells expressing the ␤A subunit and calibrated against human recombinant activin A (Genentech Research Reagents Program, South San Francisco, CA), was used as a standard. Sample medium from primary tumors was concentrated approximately 10-fold in a 10,000 mol wt cutoff centricon (Amicon, Beverly, MA). Activin was dissociated from binding proteins by treatment with an equal volume (125 L) of 8% SDS and incubation at 95 C for 10 min. Assays were developed using streptavidin-alkaline phosphatase (diluted 1:2000) and p-nitrophenyl phosphate. The interassay coefficient of variation was 16% and the intraassay coefficient of variation was 12%. The sensitivity of this assay was 5 ng/mL. Inhibin A cross-reactivity was Ͻ0.1%.
Serum activin A was measured using the same assay after it had become commercially available (Serotec) (30) , because of the greater sensitivity needed for serum measurements. The assay procedure differed from the previous in that an Ampak substrate kit (Dako Diagnostics, Cambridgeshire, UK), including addition of 1 L 1 m MgCl 2 /mL substrate, was used to develop the assay. The assay sensitivity was 80 pg/mL, the value of the lowest standard. The inter-and intraassay coefficients of variation were Ͻ7%. There was no cross-reactivity reported with inhibin A, FS, activin B, or inhibin B.
Free FS two-site monoclonal antibody immunoradiometric assay. Free FS was measured in a two-site immunoradiometric assay using two monoclonal antibodies to nonoverlapping epitopes as previously described (31) . The intra-and interassay coefficients of variation were between 2.7-4.9% and 7.8 -11.7%, respectively. The assay detection limit was 0.5 ng/mL. No cross-reactivity was observed with inhibin A, activin A, or ␣ 2 macroglobulin (31) .
Total FS RIA. Because FS-activin complexes would not be detected by the free FS assay, tumor media was also analyzed using a total FS assay that utilizes a polyclonal antibody to human FS 288 (32) . The intra-and interassay coefficients of variation were less than 8% and 11%, respectively. The assay detection limit was 3.2 ng/mL, and no cross-reactivity was demonstrated with inhibin A, activin A, or ␣ 2 macroglobulin.
RNA extraction
Epithelial ovarian tumors. Frozen tumor sample (0.1-0.4 g) was homogenized in 4 mL Trizol (Gibco BRL) using a mechanical tissue homogenizer (PowerGen 125, Fischer Scientific, Pittsburgh, PA), and mRNA extracted according to the manufacturer's instruction. Total RNA (25-50 g) was treated with 5 U deoxyribonuclease I, Amp Grade (Gibco BRL) in a 50-L reaction volume, and the resulting sample reextracted using Trizol. The RNA concentration at each step was determined using spectrophotometric analysis at 260 nm.
Normal epithelium. mRNA was extracted from normal epithelium using Trizol, as above, after addition of 10 -20 g Escherichia coli transfer RNA (tRNA) to facilitate maximal mRNA recovery. Normal epithelium was not subject to DNase treatment.
Normal epithelium and epithelial ovarian tumors in culture.
RNA from tumor and normal epithelium in culture was extracted with Trizol after 1 month in culture and treated (1 g) with 1 U DNase I, as above, in a 10-L reaction volume.
RT-PCR analysis
Complementary DNA (cDNA) was obtained by RT at 42 C for 45 min in a 20-L reaction mixture containing 1 g RNA, 0.25 mm of each deoxynucleotide triphosphate, 5 m oligo deoxythymidine, 200 U Superscript II (Gibco) reverse transcriptase, and 18 U RNase inhibitor (Promega, Madison, WI). The cDNA from three separate RT reactions was pooled and subjected to PCR for ␣; ␤A; ␤B; FS (315 and 288); activin type IA, IB, II, and IIB receptors; and ␤-actin targets.For normal epithelium, however, the amount of mRNA could not be quantified because of the addition of tRNA to the extraction, and 5-10 g of tRNA ϩ epithelial RNA was added to each reaction. The PCR reaction was performed in a volume of 25 L containing 0.2 mm of each deoxynucleotide triphosphate, 1 m 5Ј and 3Ј primers, 1 unit Taq polymerase (Promega), and 1 Ci nucleotide triphosphate ([ 32 P]deoxycytidine triphosphate), to which 5 L of the RT reaction was added. All primers crossed at least one intron to assure that the band resulting from PCR analysis was because of mRNA, except in the case of ␤B (see Table 1 ). For this primer product, a control tube was included for each sample with no added RT enzyme, resulting in no detectable band in any sample. In addition, the primer used to detect FS was designed to cross intron 5, which is alternately spliced for transcription of FS 288. Thus, using one primer set, bands of two sizes could be detected for FS, and were shown by Southern blot and sequencing to represent FS 288 (835-kilobase band) and 315 (531-kilobase band) (33) .
Increased sensitivity RT-PCR. During the course of the study, it was noted that the ␣, ␤A, and ␤B targets were inconsistently detected in some samples. Pretreatment of the cDNA before PCR using 3 U RNase at 37 C for 20 min resulted in consistent detection and greater sensitivity. The tumor samples were reprocessed using this method, and results analyzed separately for ␣, ␤A, and ␤B.
All samples were overlaid with mineral oil, and amplification achieved using a thermal cycler (DNA Thermal
Five microliters of the PCR reaction was electrophoresed in a 5% polyacrylamide gel in Tris-borate-EDTA buffer. Autoradiography was carried out for 1-2 h at room temperature, and each band scanned on a densitometer with automatic background subtraction.
Based on the consistent and qualitatively greater signal from the ␤A PCR band (relative to ␤-actin diluted 10 4 ) in cultured samples compared with primary tumors (Fig. 1A) , we developed semiquantitative conditions to compare ␤A expression between the seven tumors in culture and seven paired primary tumor samples. PCR conditions were optimized so that the reaction was in the exponential phase when cDNA (after RT) was diluted 1:100 for ␤A and 1:10,000 for ␤-actin, and amplification carried out for 30 cycles, as described above. Both targets were run for all samples in the same reaction under identical conditions. The absorption of the resulting ␤A band was normalized to the absorption of the band for ␤-actin.
Verification of PCR products. The indentities of PCR products were verified either by Southern blot analysis using an internal oligonucleotide or by sequencing, as previously described (16, 33) , except in the case of ␤B for which new primers had been synthesized in this study. The Southern blot analysis for ␤B was carried out exactly as described previously (16) using an internal oligonucleotide probe CGC-CTT-CCC-GAG-CAC-ACA-TAA-AAG-CAC-AAA-GAC-A corresponding to nucleotides 1461-1494 (34) . The single band seen after electropheresis was detected by the labeled ␤B primer, thus verifying its identity (data not shown). GTT-TTC-TGT-CCA-GGC-AGC-TCC-ACA 538-561 46 FS 3Ј GGC-TAT-GTG-AAC-ACT-GAA-CAC-TTA 1335-1358 ActIa 5Ј
GCC-CAA-GGT-CAA-CCC-CAA-ACT-CT 178-200 47 ActIa 3Ј
GGA-TTT-TCC-TTT-AGT-GGG-CAG-CT 420-442 ActIb 5Ј
ACC-AGC-TGC-CTC-CAG-GCC-AAC-TA 109-131 47 ActIb 3Ј
GTG-CTC-AGG-CTC-CTT-GAG-GTG-AC
332-354 ActII 5Ј
GAA-AAT-GGG-AGC-TGC-TGC-AAA-GTT-G 170-194 48 ActII 3Ј
GTA-GGC-CAT-CTT-GTG-ATG-CCT-GTA-C 653-677 ActIIb 5Ј
CAA-CTT-CTG-CAA-CGA-GCG-CTT 322-342 49 ActIIb 3Ј
GCG-CCC-CCG-AGC-CTT-GAT-CTC 584-604 ␤-Actin 5Ј ATC-CTG-CTG-CTG-GAC-CTG 564-581 50 ␤-Actin 3Ј
GCT-GAT-CCA-CAT-CTG-CTG 1098-1115
Thymidine incorporation assay
Cells cultured from tumor and normal epithelium were harvested at approximately 80% confluence and plated in a 24-well plate (1 ϫ 10 4 cells/well) in RPMI medium supplemented with 10% FBS. At 24, 48, and 96 h, medium was changed to control medium (RPMI with 10% FBS) or control medium supplemented with recombinant human activin A 100 ng/mL, recombinant human FS 288 100 ng/mL (National Hormone Pituitary Program, NICHD) or recombinant human epidermal growth factor (EGF) 10 ng/mL (Sigma Chemical Co., St. Louis, MO). Doses of activin and FS were selected based on their ability to maximally stimulate or inhibit growth in a study of ovarian tumor cell lines (16) . At 96 h, 1 Ci [ 3 H]thymidine (6.7 Ci/mmol; NEN, Boston, MA) was added to the medium, and cells incubated for 18 -24 h. DNA was subsequently isolated using 10% trichloroacetic acid and solubilized in 1 n NaOH. Each experiment was performed in duplicate.
Statistical analysis
Comparison between the normalized absorbance of PCR bands for ␤A in primary and cultured tumors was made using Student's t test. Correlation between medium or serum activin A or inhibin and tumor subtype was evaluated using ANOVA and a Tukey honest significant difference test for post-hoc comparisons. In addition, a comparison of pre-and postoperative activin A levels was made using a Student's t test. A P value of Ͻ0.05 was considered significant.
Results
mRNA expression
Epithelial ovarian tumors. All epithelial ovarian tumors expressed mRNA for ␣, ␤A, and ␤B subunits; FS 288 and 315; and the activin type IA, IB, II, and IIB receptors. ␤A mRNA expression in tumors after 1 month in culture (n ϭ 7) was 3-fold greater than that of the matched primary tumors (0.86 Ϯ 0.17 vs. 0.28 Ϯ 0.09; P Ͻ 0.01) (Fig. 1B) .
Normal epithelium. Normal epithelium expressed mRNA for FS 288 and 315, and the activin type IA, IB, II, and IIB receptors ( Table 2, 1-8 ). There was detectable ␣ subunit mRNA expression in 3/8 samples but barely detectable ␤A subunit mRNA expression in only 2/8 samples. After 1 month in culture, however, ␣ subunit mRNA was undetectable, whereas ␤A was abundantly expressed in the two samples.
Increased sensitivity RT-PCR.
RNase treatment of cDNA before PCR resulted in consistent detection of ␣, ␤A, and ␤B subunits in all tumors (n ϭ 25) and tumors in culture (n ϭ 3). In one additional normal epithelial sample, ␣ subunit but not ␤A or ␤B was detectable (Table 2, 9), consistent with the results above.
Protein secretion
Epithelial ovarian tumors. Activin protein was secreted by 24/25 (96%) primary tumors (range 0.2-155.8 ng/mL). Total inhibin was secreted by only 2/25 (8%) tumors. These 2 tumors belonged to the group of 4 tumors of mucinous subtype; a borderline mucinous cystadenoma (10 pg/mL) and a low-grade mucinous cystadenocarcinoma (920 pg/ mL), which also secreted dimeric inhibin A (118 pg/mL). FS was secreted by 10/13 (77%) tumors (range 0.5-16 ng/mL), however, free FS was not detectable in the medium of any tumor (0/25; Fig. 2 ). Activin A secretion correlated significantly with tumor type (P Ͻ 0.05); mucinous tumors secreted significantly higher levels of activin A than serous tumors, although the numbers were small, and the ranges overlapped (102.1 Ϯ 32.8 vs. 31.9 Ϯ 10.9 ng/mL; Fig. 3A) . Mucinous tumors also secreted significantly higher levels of total inhibin than serous tumors (0.23 Ϯ 0.23 vs. 0 ng/mL; P Ͻ 0.05), although no overall correlation was seen between total in- hibin and tumor subtype. There was no correlation between inhibin or activin A secretion and tumor grade.
Normal epithelium. Normal epithelium (n ϭ 2) secreted total inhibin (0.63 Ϯ 0.53 ng/mL). Dimeric inhibin A, activin A, free, and total FS were all undetectable.
Activin A levels in serum. Activin A levels in pre-and postmenopausal subjects with epithelial ovarian carcinoma were compared with values in normal postmenopausal women (0.65 Ϯ 0.18 ng/mL) and normal premenopausal women on the day of menses (0.66 Ϯ 0.12 ng/mL). Because the activin A levels were not significantly different in pre-and postmenopausal controls, the groups were pooled, and an elevated activin A level was defined as Ͼ3 sd above the mean for all normal subjects (1.10 ng/mL). Serum activin A levels were elevated in 13/33 subjects (39%), with the majority of elevated activin levels in subjects having the serous subtype (Fig. 3B ). The average activin A level in subjects with epithelial tumors (1.13 Ϯ 0.66 ng/mL) and in the subset of subjects with serous tumors (1.33 Ϯ 0.17 ng/mL) and undifferentiated tumors (1.45 Ϯ 0.76 ng/mL) was significantly higher than in controls (0.65 Ϯ 0.15 ng/mL; P Ͻ 0.05 for all groups). In the subset of subjects with elevated activin A levels in whom both pre-and postoperative serum samples were available, there was a slight decrease in activin A postoperatively (1.53 Ϯ 0.16 vs. 1.05 Ϯ 0.20 ng/mL), although this result did not reach significance (Fig. 4) . In the 6 subjects in whom tumor tissue was also available, there was no correlation between circulating activin A levels and secretion by the tumor in vitro. There was also no correlation between circulating activin A level and tumor subtype.
Effects of activin, FS, and EGF on cell proliferation
In tumor epithelium cultures, activin treatment (100 ng/ mL) resulted in increased proliferation in 1/6 tumors, whereas FS treatment (100 ng/mL) increased proliferation in 2/6 tumors. EGF treatment (10 ng/mL), used as a positive 
Normal epithelium was scraped from the surface of ovaries and mRNA was extracted immediately (no culture) or after 30 days in culture. a Relative absorbance for PCR bands. ϩ/Ϫ, 0 -100 units; ϩ, Ͼ100 -1000 units; ϩϩ, Ͼ1000 -2000 units; ϩϩϩ, Ͼ2000 units; ND, not done. control, resulted in a significant increase in proliferation. In normal epithelium cultures (n ϭ 2), EGF treatment resulted in a significant increase in proliferation, whereas no consistent increase or decrease was seen with activin or FS treatment.
Discussion
The repeated growth and rupture of ovarian epithelium during follicular development and ovulation over the course of a female's reproductive lifetime creates a situation in which growth factors play a critical role in the cycle of continued epithelial proliferation and repair. These same growth factors may also promote the growth of neoplastic epithelium (35) . Activin, established as a growth and differentiation factor in a wide variety of tissues and present in abundance in ovarian granulosa cells (36) and follicular fluid (37) , is a possible candidate for this action. Using a comprehensive protocol to characterize activin, inhibin, FS, and activin receptor mRNA expression and protein secretion in epithelial ovarian neoplasia, our results demonstrate ␣, ␤A, and ␤B subunit; FS; and activin type I and II receptor mRNA expression and activin A secretion by virtually all of the epithelial ovarian tumors examined. Further, activin A is secreted in 10-to 20-fold excess over FS, the protein that binds and neutralizes activin's action (17) (18) (19) , whereas total inhibin is secreted by only a subset of mucinous tumors, a finding consistent with previous immunohistochemical studies (38) . In contrast, normal ovarian epithelium expresses little ␤A subunit mRNA and secretes no detectable activin A but rather favors ␣ subunit production. Taken together, these results demonstrate that epithelial ovarian tumors produce bioavailable activin, and support the possibility that activin A may play a role in tumor development and/or growth.
Previous studies using normal human granulosa cells (39, 40) and a gonadal stromal tumor cell line (20) , and our own studies using epithelial carcinoma cell lines (16) , indicate that activin increases cellular proliferation, whereas FS blocks this effect. We were unable, however, to demonstrate a consistent activin effect on proliferation in normal or neoplastic ovarian epithelium in this study, perhaps because of: 1) absence of a necessary cofactor or growth factor secreted by the stroma and required for activin action; 2) loss of contact with other epithelial cells after subculturing; and/or 3) the inherent ovarian epithelial cell senescence after passaging in culture (41) . Our data does, however, reveal greater ␤A subunit mRNA expression in normal and neoplastic ovarian epithelial cells in culture. This increase may be because of upregulation of gene expression by factors involved in cell proliferation, or absence of inhibitory factors secreted by the surrounding stroma and lost in culture. Taken together, the evidence suggests that activin production increases in proliferating ovarian epithelium and may act in an autocrine or paracrine manner to stimulate growth. Thus, if the frequent cell division required for epithelial repair results in a genetic mutation and transformation, activin may act in a permissive manner to promote neoplastic cell growth. Alternatively, loss of an inhibitory growth factor such as tranforming growth factor-␤ (42), or a mutation resulting in dysregulation of the control or response mechanism of activin could lead directly to uncontrolled growth.
Despite inhibin ␣ subunit mRNA expression by all tumors, secretion was demonstrated by only 2 mucinous tumors. This discrepancy suggests: 1) a translational block; 2) mutation or alternate processing of the ␣ subunit rendering it undetectable in the Monash assay; and/or 3) secretion at levels below the assay detection limit. In contrast, detectable inhibin was secreted by 2/2 normal epithelial cultures. These findings suggest the possibility that ␣ subunit could act as a tumor suppressor as was initially described in the ␣ subunit knockout mouse (14) . Rather than tumorigenesis resulting from deletion of a tumor suppressor gene, however, ␣ subunit may act as a tumor suppressor protein by dimerizing with ␤ subunit, thus preventing activin formation and decreasing proliferative potential. The difference in tumor subtypes in the mouse (gonadal stromal tumors) and human (epithelial tumors) could be related to the potentially different tumor suppressor mechanisms or more likely to the differing ovarian biology in the two species, because epithelial tumors are rare in the mouse (43) .
Activin A levels are increased in the serum of subjects with epithelial tumors as demonstrated by an elevated mean activin A level for all subjects and elevated levels in a significant number of subjects compared to controls. The majority of elevated levels are accounted for by subjects with serous and undifferentiated tumors and the subset of mixed tumors containing both serous and endometrioid components. Therefore, measurement of activin A levels in serum may provide information additive to serum ␣ inhibin levels, which are elevated in many patients with mucinous but not serous tumors (12, 13) . In contrast to these serum findings, however, mucinous tumors secrete the highest level of activin A in vitro and are the only epithelial tumor subtype that demonstrates positive staining for immunoreactive activin (38) . The small number of mucinous tumors examined or the unavailability of paired tissue and serum samples may account for the discrepancy between serum and in vitro data, although we cannot exclude the possibility that mucinous tumors secrete an activin binding protein that sequesters activin locally. Based on the large number of subjects with elevated activin A levels and the apparent postoperative decrease in subjects with preoperative serum elevation, it appears that tumor production of activin A may contribute to serum levels. Thus, activin A may potentially serve as a tumor marker for serous and undifferentiated tumors. Further investigation using a larger number of subjects is needed to document a postoperative fall in activin A and to correlate in vitro activin A production with serum levels.
In summary, the data provided here clearly demonstrate activin subunit and receptor mRNA expression and secretion of activin A in excess of the activin binding protein FS in epithelial ovarian cancers but not normal epithelium. Furthermore, circulating activin A levels are elevated in a subset of epithelial tumors. Therefore, further investigation of activin A as both a potential growth factor and a tumor marker is warranted.
